New drug extends life of men with advanced prostate cancer

There’s good news for men’s health today with trials in the UK of a new prostate cancer drug, radium-223 chloride – also known as Alpharadin TM – being halted because the results were so successful. Doctors at at the Royal Marsden Hospital in London found that the experimental treatment relieved pain while causing only minor side effects, leading them to decide it would be unethical not offer the drug to all 922 prostate cancer volunteers taking part in the study. The UK trials, part of a wider Phase III trial of Alpharadin TM conducted in more than 150 hospitals in 19 countries, saw a 30 per cent lower death rate in those receiving the experimental drug record than those receiving … Continue reading